Literature DB >> 30083876

Weight changes associated with antiepileptic mood stabilizers in the treatment of bipolar disorder.

Koen P Grootens1,2, Anna Meijer3,4, Erwin G Hartong5, Bennard Doornbos6, P Roberto Bakker7,8, Asmar Al Hadithy9, Kirsten N Hoogerheide10, Frans Overmeire11, Radboud M Marijnissen4,12, Henricus G Ruhe13,4.   

Abstract

OBJECTIVE: To present up-to-date information and recommendations on the management of body weight changes during the use of antiepileptic mood stabilizers in bipolar disorder to help clinicians and patients make well-informed, practical decisions. DATA SOURCES: Umbrella review. Systematic reviews and meta-analyses on the prevention, treatment, and monitoring of body weight changes as a side effect of the mood stabilizers valproate, lamotrigine, topiramate, and carbamazepine were identified in Embase (2010-2015, no language restrictions). STUDY SELECTION: The search yielded 18 relevant publications on antiepileptic mood stabilizers and weight changes in bipolar disorder. DATA EXTRACTION: Relevant scientific evidence was abstracted and put into a clinical perspective by a multidisciplinary expert panel of clinicians with expertise in the treatment of bipolar disorders across all age groups and a patient representative.
RESULTS: Valproate has been proven to be associated with weight gain in up to 50% of its users, and can be detected 2-3 months after initiation. Carbamazepine has been proven to have a low risk of weight gain. Lamotrigine and topiramate are associated with weight loss. Other option for this sentence = Weigth gain has been proven to be associated with valproate use in up to 50% of its users, and can be detected within 2-3 months after initiation.
CONCLUSION: Each antiepileptic mood stabilizer has specific effects on body weight and accordingly requires a discrete education, prevention, monitoring, and treatment strategy. Clinicians are recommended to adopt an active, anticipatory approach, educating patients about weight change as an important side effect in order to come to informed shared decisions about the most suitable mood stabilizer.

Entities:  

Keywords:  Anti-obesity agents; Bipolar disorder; Body weight changes; Carbamazepine; Lamotrigine; Topiramate; Valproate; Weight gain; Weight loss

Mesh:

Substances:

Year:  2018        PMID: 30083876     DOI: 10.1007/s00228-018-2517-2

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  25 in total

Review 1.  The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid metabolic disorders.

Authors:  Roger S McIntyre; Mohammad Alsuwaidan; Benjamin I Goldstein; Valerie H Taylor; Ayal Schaffer; Serge Beaulieu; David E Kemp
Journal:  Ann Clin Psychiatry       Date:  2012-02       Impact factor: 1.567

Review 2.  Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis.

Authors:  Lawrence Maayan; Julia Vakhrusheva; Christoph U Correll
Journal:  Neuropsychopharmacology       Date:  2010-03-24       Impact factor: 7.853

Review 3.  Topiramate for migraine prophylaxis in pediatric patients.

Authors:  Tamara L Deaton; Laurie S Mauro
Journal:  Ann Pharmacother       Date:  2014-02-24       Impact factor: 3.154

Review 4.  Weight considerations in psychotropic drug prescribing and switching.

Authors:  Mehrul Hasnain; W Victor R Vieweg
Journal:  Postgrad Med       Date:  2013-09       Impact factor: 3.840

5.  Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013.

Authors:  Lakshmi N Yatham; Sidney H Kennedy; Sagar V Parikh; Ayal Schaffer; Serge Beaulieu; Martin Alda; Claire O'Donovan; Glenda Macqueen; Roger S McIntyre; Verinder Sharma; Arun Ravindran; L Trevor Young; Roumen Milev; David J Bond; Benicio N Frey; Benjamin I Goldstein; Beny Lafer; Boris Birmaher; Kyooseob Ha; Willem A Nolen; Michael Berk
Journal:  Bipolar Disord       Date:  2012-12-12       Impact factor: 6.744

Review 6.  Practitioner review: Long-term pharmacological treatment of pediatric bipolar disorder.

Authors:  Covadonga M Díaz-Caneja; Carmen Moreno; Cloe Llorente; Ana Espliego; Celso Arango; Dolores Moreno
Journal:  J Child Psychol Psychiatry       Date:  2014-06-06       Impact factor: 8.982

Review 7.  Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications.

Authors:  A Verrotti; C D'Egidio; A Mohn; G Coppola; F Chiarelli
Journal:  Obes Rev       Date:  2010-09-06       Impact factor: 9.213

Review 8.  Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis.

Authors:  Juan Pablo Domecq; Gabriela Prutsky; Aaron Leppin; M Bassam Sonbol; Osama Altayar; Chaitanya Undavalli; Zhen Wang; Tarig Elraiyah; Juan Pablo Brito; Karen F Mauck; Mohammed H Lababidi; Larry J Prokop; Noor Asi; Justin Wei; Salman Fidahussein; Victor M Montori; Mohammad Hassan Murad
Journal:  J Clin Endocrinol Metab       Date:  2015-01-15       Impact factor: 5.958

9.  The role of valproate in metabolic disturbances in bipolar disorder patients.

Authors:  Hui Hua Chang; Yen Kuang Yang; Po Wu Gean; Hui Chun Huang; Po See Chen; Ru Band Lu
Journal:  J Affect Disord       Date:  2010-01-13       Impact factor: 4.839

Review 10.  Topiramate add-on for drug-resistant partial epilepsy.

Authors:  Jennifer Pulman; Nathalie Jette; Jonathan Dykeman; Karla Hemming; Jane L Hutton; Anthony G Marson
Journal:  Cochrane Database Syst Rev       Date:  2014-02-25
View more
  9 in total

Review 1.  Drugs Affecting Body Weight, Body Fat Distribution, and Metabolic Function-Mechanisms and Possible Therapeutic or Preventive Measures: an Update.

Authors:  Ann A Verhaegen; Luc F Van Gaal
Journal:  Curr Obes Rep       Date:  2021-01-05

Review 2.  Psychotropic Medications in Metabolic and Bariatric Surgery: Research Updates and Clinical Considerations.

Authors:  Janelle W Coughlin; Kristine J Steffen; Sanjeev Sockalingam; James E Mitchell
Journal:  Curr Psychiatry Rep       Date:  2022-01-25       Impact factor: 5.285

3.  Valproate-Induced Epigenetic Upregulation of Hypothalamic Fto Expression Potentially Linked with Weight Gain.

Authors:  Huan Zhang; Ping Lu; Hui-Ling Tang; Hua-Juan Yan; Wei Jiang; Hang Shi; Si-Yu Chen; Mei-Mei Gao; Xiang-Da Zeng; Yue-Sheng Long
Journal:  Cell Mol Neurobiol       Date:  2020-06-04       Impact factor: 5.046

4.  Plasma Calcitonin Gene-Related Peptide: A Potential Biomarker for Diagnosis and Therapeutic Responses in Pediatric Migraine.

Authors:  Pi-Chuan Fan; Ping-Hung Kuo; Ming Tatt Lee; Shu-Hui Chang; Lih-Chu Chiou
Journal:  Front Neurol       Date:  2019-01-24       Impact factor: 4.003

Review 5.  Elevated Brain Glutamate Levels in Bipolar Disorder and Pyruvate Carboxylase-Mediated Anaplerosis.

Authors:  Jun Shen; Jyoti Singh Tomar
Journal:  Front Psychiatry       Date:  2021-02-23       Impact factor: 4.157

Review 6.  Efficacy and safety of lamotrigine in the treatment of bipolar disorder across the lifespan: a systematic review.

Authors:  Frank M C Besag; Michael J Vasey; Aditya N Sharma; Ivan C H Lam
Journal:  Ther Adv Psychopharmacol       Date:  2021-10-08

7.  Comparison of Rates of Type 2 Diabetes in Adults and Children Treated With Anticonvulsant Mood Stabilizers.

Authors:  Jenny W Sun; Jessica G Young; Aaron L Sarvet; L Charles Bailey; William J Heerman; David M Janicke; Pi-I Debby Lin; Sengwee Toh; Jason P Block
Journal:  JAMA Netw Open       Date:  2022-04-01

8.  Carbamazepine Enhances Adipogenesis by Inhibiting Wnt/β-catenin Expression.

Authors:  Dong Uk Im; Sang Chon Kim; Gia Cac Chau; Sung Hee Um
Journal:  Cells       Date:  2019-11-18       Impact factor: 6.600

9.  Cardiovascular risk in patients with severe mental illness in Italy.

Authors:  Virginio Salvi; Andrea Aguglia; Francesco Barone-Adesi; Davide Bianchi; Chiara Donfrancesco; Filippo Dragogna; Luigi Palmieri; Gianluca Serafini; Mario Amore; Claudio Mencacci
Journal:  Eur Psychiatry       Date:  2020-10-26       Impact factor: 5.361

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.